Global PCSK9 Inhibitors Market to 2030 – News, Epidemiology & Forecast –


DUBLIN – (COMMERCIAL THREAD) – The report “PCSK9 Inhibitors (PCSK9i) – Market Insights, Epidemiology, and Market Forecast – 2030” has been added to offer.

This report provides an in-depth understanding of PCSK9i, historical and predicted epidemiology as well as PCSK9 inhibitor market trends in US, EU5 (Germany, France, Italy, Spain and UK) and UK. Japan.

The PCSK9 Inhibitors Market report provides the pathological areas, emerging drugs, PCSK9 Inhibitors market share of individual therapies, current and forecasted PCSK9 Inhibitors market size from 2018 to 2030, segmented by seven major markets. The report also covers the prescribing eligibility criteria of current PCSK9 inhibitors, approved and emerging therapies, market drivers, market barriers and unmet medical needs to organize the best opportunities and assess the underlying potential. of the market.

Main conclusions

In 2020, the total number of prevalent familial hypercholesterolemia cases was 3.1 million cases in 7MM and is expected to increase during the study period, i.e. 2018-2030.

The disease epidemiology covered in the report provides the historical and predicted epidemiology of Von Hippel-Lindau disease [segmented as Total prevalent cases of Familial Hypercholesterolemia, Total diagnosed cases of Familial Hypercholesterolemia, Total type-specific cases of Familial Hypercholesterolemia, Total age group-specific cases of Familial Hypercholesterolemia, Total mutation-specific cases of Familial Hypercholesterolemia, Total risk factor-specific cases of PCSK9 Inhibitors in Prophylactic/Preventive setting, and Total Treated cases of PCSK9 Inhibitors] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain and United Kingdom) and Japan from 2018 to 2030.

Companies mentioned

  • Sanofi

  • Regeneron Pharmaceuticals

  • Amgen

  • Novartis

  • Alnylam Pharmaceuticals

  • Therapeutic LIB

  • AstraZeneca and Ionis Pharmaceuticals

  • CiVi Biopharma

Reasons to buy

  • The report will help develop business strategies by understanding the trends shaping and driving the PCSK9 Inhibitors market.

  • To understand the future competition in the PCSK9 Inhibitors market and an in-depth look at the major drivers and barriers in the market.

  • Organize sales and marketing efforts by identifying the best opportunities for PCSK9 inhibitors in the United States, Europe (Germany, France, Italy, Spain and United Kingdom) and Japan.

  • Identifying strong future players in the market will help design strategies that will help get ahead of the competition.

  • Organize sales and marketing efforts by identifying top opportunities for the PCSK9 Inhibitors market.

  • To understand the future competition in the PCSK9 inhibitors market.

Main topics covered:

1. Key information

2. Presentation of the report

3. PCSK9 Inhibitors Market Overview at a Glance

3.1. Market share (%) Distribution of PCSK9 inhibitors in 2018

3.2. Market share (%) Distribution of PCSK9 inhibitors in 2030

4. Summary of PCSK9 (PCSK9i) Inhibitors

5. Key events

5.1. Epidemiology and market methodology

6. Background and overview of PCSK9 inhibitors (PCSK9i)

7. Presentation

7.1. PCSK9 gene biology

7.2. Functional mechanics of PCSK9

7.3. PCSK9 Inhibitors

7.4. PCSK9 inhibition strategies

7.5. The approval status of PCSK9 inhibitors

7.6. Areas of disease of PCSK9 inhibitors

7.6.1. Primary hyperlipidemia

7.6.2. Prevention of myocardial infarction, stroke and unstable angina requiring hospitalization

8. Guidelines

8.1. ESC / EAS guidelines for the management of dyslipidemias

8.2. American College of Cardiology / American Heart Association Working Group on Clinical Practice Guidelines

8.3. Recommendations from a group of experts from the National Lipid Association

8.4. Recommendations of the Spanish Arteriosclerosis Society (SEA)

8.5. NICE guidelines

8.6. Japan Atherosclerosis Society (JAS) Guidelines for the Prevention of Atherosclerotic Cardiovascular Disease

8.7. Comparison of guidelines

9. Epidemiology and patient population

9.1. Main conclusions

9.2. Epidemiology of PCSK9 inhibitors

9.3. Epidemiology scenario

9.3.1. Total prevalent cases of familial hypercholesterolemia

9.3.2. Total diagnosed cases of familial hypercholesterolemia

9.3.3. Total number of specific cases of familial hypercholesterolemia

9.3.4. Total Familial Hypercholesterolemia Cases by Age

9.3.5. Total mutation-specific familial hypercholesterolemia cases

9.3.6. Total cases specific to PCSK9 inhibitor risk factors in a prophylactic / preventive setting

9.3.7. Total number of treated cases of PCSK9 inhibitors

10. Patient journey

11. Main endpoints for clinical trials with PCSK9 inhibitors

12. Medicines marketed

12.1. Praluent (Alirocumab): Sanofi / Regeneron Pharmaceuticals

12.1.1. Description of the drug

12.1.2. Regulatory milestones

12.1.3. Other development activities

12.1.4. Pivotal clinical trial

12.1.5. Current pipeline activity in progress

12.2. Repatha (Evolocumab / AMG 145): Amgen

12.2.1. Description of the drug

12.2.2. Regulatory milestones

12.2.3. Other development activities

12.2.4. Pivotal clinical trial

12.2.5. Current pipeline activity in progress

12.3. Leqvio (Inclisiran): Novartis / Alnylam Pharmaceuticals

12.3.1. Description of the drug

12.3.2. Regulatory milestones

12.3.3. Other development activities

12.3.4. Pivotal clinical trial

12.3.5. Current pipeline activity in progress

13. Emerging therapies

13.1. LIB003 (Lérodalcibep): Therapeutic LIB

13.1.1. Description of the drug

13.1.2. Clinical development

13.1.3. Safety and efficiency

13.2. AZD8233 (LOI449): AstraZeneca and Ionis Pharmaceuticals

13.2.1. Description of the drug

13.2.2. Other development activities

13.2.3. Clinical development

13.2.4. Safety and efficiency

13.3. Cepadacursen sodium (CIVI-007): CiVi Biopharma

13.3.1. Product Description

13.3.2. Other development activities

13.3.3. Clinical development

13.3.4. Safety and efficiency

14. PCSK9 Inhibitors: 7 Major Market Reviews

14.1. Main conclusions

14.2. Market outlook

14.3. PCSK9 (PCSK9i) Inhibitors Market

14.4. PCSK9 Inhibitor Market Size

14.4.1. Total PCSK9 Inhibitor Market Size

14.4.2. PCSK9 inhibitors market size by therapies (treatment and secondary prevention)

15. Market access and reimbursement

16. KOL Views

17. Market drivers

18. Market barriers

19. SWOT analysis

20. Unmet needs

21. Annex

22. Editor skills

23. Disclaimer

24. About the publisher

For more information on this report, visit


Leave A Reply